Last reviewed · How we verify
Amylcain (naepaine)
Amylcain (generic name: naepaine) is a naepaine drug. It is currently in unknown development.
Amylcain works by interacting with a specific target in the body to produce a therapeutic effect.
Amylcain is a small molecule with the synonyms AMYLSINE HYDROCHLORIDE, NAEPAINE HCL, NAEPAINE HYDROCHLORIDE, NAEPAINE HYDROCHLORIDE, and NSC-120971.
At a glance
| Generic name | naepaine |
|---|---|
| Drug class | naepaine |
| Therapeutic area | Pain |
| Phase | unknown |
Mechanism of action
Imagine Amylcain as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that ultimately lead to the desired outcome, such as reducing symptoms or slowing disease progression.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amylcain CI brief — competitive landscape report
- Amylcain updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Amylcain
What is Amylcain?
How does Amylcain work?
What is the generic name of Amylcain?
What drug class is Amylcain in?
What development phase is Amylcain in?
Related
- Drug class: All naepaine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing